title: Dosing interval of 24hours versus 48hours between mifepristone and misoprostol administration for mid-trimester termination of pregnancy.
abstract: OBJECTIVE
  To compare the efficacy of a shorter interval (24hours) between misoprostol and mifepristone administration with that of the conventional dosing interval (48hours) for second-trimester termination of pregnancy (TOP).
  
  
  METHODS
  This was a prospective randomized, controlled, open-label study of 98 healthy women opting for mid-trimester TOP. The women were randomized to receive 200mg mifepristone orally, followed 24hours (Group 1) or 48hours (Group 2) later by misoprostol (800μg, then 400μg every 3hours). The primary outcome measure was the percentage of successful abortions within 24hours. Secondary outcome measures were the induction-to-abortion interval (measured from misoprostol administration) and the frequencies of complications and adverse effects.
  
  
  RESULTS
  The rate of successful abortions was similar with the 24-hour and 48-hour dosing intervals (95.8% and 93.6%, respectively; P=0.38). The mean induction-to-abortion interval was also comparable between the 2 groups (8.6±4.1hours versus 8.7±3.9hours; P=0.37). Nulliparous women and women with a pregnancy duration of 16weeks or more had a longer induction-to-abortion interval in both groups.
  
  
  CONCLUSIONS
  The 24-hour dosing interval between misoprostol and mifepristone administration seems to be as effective as the 48-hour dosing interval for second trimester TOP. Clinical Trial Registry India: CTRI/2011/05/001770.
authors.affiliation: Department of Gynecology and Obstetrics, Nilratan Sircar Medical College, West Bengal University of Health Sciences, Kolkata, India. Electronic address: picklu.chaudhuri@gmail.com.
authors.forename: Picklu
authors.initials: P
authors.lastname: Chaudhuri
authors.affiliation: Department of Gynecology and Obstetrics, Nilratan Sircar Medical College, West Bengal University of Health Sciences, Kolkata, India.
authors.forename: Apurba
authors.initials: A
authors.lastname: Mandal
authors.affiliation: Department of Gynecology and Obstetrics, Nilratan Sircar Medical College, West Bengal University of Health Sciences, Kolkata, India.
authors.forename: Chandana
authors.initials: C
authors.lastname: Das
authors.affiliation: Department of Gynecology and Obstetrics, Nilratan Sircar Medical College, West Bengal University of Health Sciences, Kolkata, India.
authors.forename: Arindam
authors.initials: A
authors.lastname: Mazumdar
mesh_terms: D000019:Abortifacient Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced; D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000019:Abortifacient Agents; D016595:Misoprostol; D015735:Mifepristone
keywords: Dosing interval; Mifepristone; Misoprostol; Second trimester; Termination of pregnancy